Imke Anne Maartje Ditters

Ms. Imke Anne Maartje Ditters

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
NBNadine A. M. E. van der Beek
Nadine A. M. E. van der Beek
EBEsther Brusse
Esther Brusse
APAns T. van der Ploeg
Ans T. van der Ploeg
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
HHHidde Huidekoper
Hidde Huidekoper
Background: Pompe disease is a lysosomal storage disease treated with life-long enzyme replacement therapy (ERT). Home-based ERT has been provided in the Netherlands since 2008 because it diminishes the burden of treatment, increases patient flexibility and autonomy, and is thus a more patient-centred approach to ERT. Methods: All Dutch Pompe patients receiving alglucosidase alfa infusions at home were approached to participate in a questionnaire to validate the safety of home-based ERT. Prospective data on symptoms occurring during or within 48 h after infusion and retrospective data on infusion associated reactions (IARs) in the last three months were collected four times during one year. Results: In total, 116 out of 120 eligible patients (17 classic infantile, 2 atypical infantile, 15 childhood onset and 82 adult) filled out 423 questionnaires (response rate: 88.1%). Symptoms during or after infusion were reported 27 times in 17 patients. Fatigue was the most commonly reported health complaint (in 9.5% of patients). Four health complaints were judged to be IARs and reported to the Erasmus MC University Medical Center. None of the IARs reported in this study warranted emergency clinical care. Conclusions: Our data demonstrate that home-based ERT in Pompe disease can be safely implemented as few, mostly mild, symptoms were reported during or after infusion. Insights from this study can be used as a base for implementing home-based ERT in other countries and to further optimize patient care, as unreported mild symptoms do not pose a health risk but may still be relevant to the patient.

16 June 2023 in BioDrugs
Verified
Journal Article
Open access
PDF file
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
HKHarmke A. van Kooten
Harmke A. van Kooten
NBNadine A. M. E. van der Beek
Nadine A. M. E. van der Beek
JHJacqueline F. Hardon
Jacqueline F. Hardon
GIGamida Ismailova
Gamida Ismailova
HHHidde Huidekoper
Hidde Huidekoper
Background Enzyme replacement therapy (ERT) with alglucosidase alfa is the treatment for patients with Pompe disease, a hereditary metabolic myopathy. Home-based ERT is unavailable in many countries because of the boxed warning alglucosidase alfa received due to the risk of infusion-associated reactions (IARs). Since 2008, home infusions have been provided in The Netherlands. Objectives This study aimed to provide an overview of our experience with home-based infusions with alglucosidase alfa in adult Pompe patients, focusing on safety, including management of IARs. Method We analysed infusion data and IARs from adult patients starting ERT between 1999 and 2018. ERT was initially given in the hospital during the first year. Patients were eligible for home treatment if they were without IARs for multiple consecutive infusions and if a trained home nurse, with on-call back-up by a doctor, was available. The healthcare providers graded IARs. Results We analysed data on 18,380 infusions with alglucosidase alfa in 121 adult patients; 4961 infusions (27.0%) were given in hospital and 13,419 (73.0%) were given at home. IARs occurred in 144 (2.9%) hospital infusions and 113 (0.8%) home infusions; 115 (79.9% of 144) IARs in hospital and 104 (92.0% of 113) IARs at home were mild, 25 IARs (17.4%) in hospital and 8 IARs (7.1%) at home were moderate, and very few severe IARs occurred (4 IARs in hospital [2.8%] and 1 IAR at home [0.9%]). Only one IAR in the home situation required immediate clinical evaluation in the hospital. Conclusion Given the small numbers of IARs that occurred with the home infusions, of which only one was severe, we conclude that alglucosidase alfa can be administered safely in the home situation, provided the appropriate infrastructure is present.

19 September 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
HKHarmke A. van Kooten
Harmke A. van Kooten
NBNadine A. M. E. van der Beek
Nadine A. M. E. van der Beek
APAns T. van der Ploeg
Ans T. van der Ploeg
HHHidde Huidekoper
Hidde Huidekoper
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
Background: Pompe disease is a lysosomal storage disease characterised by skeletal and respiratory muscle weakness. Since 2006, enzyme replacement therapy (ERT) with alglucosidase alfa has been available. ERT significantly improves the prognosis of patients with Pompe disease. The effect of high antibody titres on treatment response in adults with late-onset Pompe disease (LOPD) remains unclear but may contribute to interpatient variation. We therefore conducted a systematic review on this subject. Methods: A systematic search was performed in Embase, Medline Ovid, Web of Science, Psych Info Ovid, Cochrane (Clinical Trials only), and Google Scholar (random top-200). Articles were included if they involved adults with LOPD treated with alglucosidase alfa and mentioned anti-rhGAA antibodies or antibody titres. In addition, articles mentioning dosages different from the standard recommended dosage were included. Results: Our literature search retrieved 2562 publications, and 17 fulfilled our selection criteria, describing 443 cases. Seven publications reported on anti-rhGAA antibody titres on a group level, with the percentage of patients with a high titre as defined in the included articles ranging from 0–33%. Six publications reported on the effect of anti-rhGAA antibody titre on clinical course, and four found no correlation. Two studies reported a negative effect on treatment. The first study found a greater improvement in Medical Research Council (MRC) score in patients with no detectable antibody titre. In the second study, a patient discontinued ERT due to a declining neuromuscular state as a result of high anti-rhGAA antibody titres. Seven publications reported on 17 individual patients with a high antibody titre (range 1:12,800–1:3,906,250). In only two cases were high-sustained neutralising antibodies reported to interfere with treatment efficacy. Conclusions: No clear effect of anti-rhGAA IgG antibodies on treatment response could be established for the majority of LOPD patients with a high antibody titre. In a minority of patients, a clinical decline related to (possible) interference of anti-rhGAA antibodies was described.

13 April 2026 in Genetics in Medicine
Verified
Journal Article
Open access
MTMaudy T.M. Theunissen
Maudy T.M. Theunissen
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
HKHarmke A. van Kooten
Harmke A. van Kooten
PDPieter A. van Doorn
Pieter A. van Doorn
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
NBNadine A.M.E. van der Beek
Nadine A.M.E. van der Beek
Anti-recombinant human acid α-glucosidase (rhGAA) antibodies can develop in adult Pompe patients receiving enzyme replacement therapy (ERT), but their long-term impact on clinical treatment outcomes is currently unclear. Pompe patients starting ERT ≥18 years of age were monitored for anti-rhGAA antibody titers (at start of ERT and designated time points thereafter) and its neutralizing activity. Six-minute walk test and forced vital capacity were assessed to evaluate clinical outcomes. We studied the antibody titer course (n = 930) of 111 patients. High peak titers (≥31,250) were found in 34/111 patients, with high sustained antibody titers in 21/34. High titers were linked to more infusion associated reactions (IARs; P = .008). Patients with high peak antibody titers had more stable supine lung function and 6-minute walk test distance compared with those with high sustained antibody titers (P =.02) or low/intermediate titers (P =.03). No other group-level differences in outcomes were found. Neutralizing activity was detected in 9 patients without group-level impact; however, this activity or high antibody levels negatively affected disease course in some. High (sustained) antidrug antibody titers are associated with an increased risk of IARs. Although they do not appear to significantly impact clinical outcomes at the group level, their (neutralizing) effect can negatively affect disease course in individual patients.

20 July 2026 in BioDrugs
Verified
Journal Article
Open access
PDF file
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
HHHidde Huidekoper
Hidde Huidekoper
JHJacqueline F. Hardon
Jacqueline F. Hardon
MKMichelle E. Kruijshaar
Michelle E. Kruijshaar
APAns T. van der Ploeg
Ans T. van der Ploeg
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
Introduction Enzyme replacement therapy (ERT) is the standard treatment for patients with Pompe disease, a hereditary metabolic myopathy. While ERT in the home situation is increasingly common in adults with Pompe disease, experience in children remains limited due to higher dosing requirements and increased risk of infusion-associated reactions (IARs). We analysed the results of the in-hospital and home-based infusion programme applied in the Netherlands to children since 1999 to provide guidance. Methods We studied hospital and home-based infusions administered to children with Pompe disease (i.e., classic infantile, atypical infantile, and childhood onset phenotypes) who started ERT between 1999 and 2022 and analysed the characteristics of patients and IARs. The IARs were graded by healthcare providers. Results A total of 11,898 infusions with recombinant human \(\alpha\)-glucosidase (rhGAA) were administered in 52 Pompe patients (27 classic infantile, two atypical infantile and 23 childhood onset phenotypes). Of these, 5278 infusions (44.4%) were given in hospital and 6620 (55.6%) were administered at home. IARs occurred in 458 hospital infusions (8.7%) and 110 home infusions (1.7%). The majority of IARs (87.1%) occurred in patients with the classic infantile phenotype. Most IARs were mild; only 21 severe IARs were reported, two of which occurred at home. All IARs could be managed adequately. Conclusion Recombinant human α-glucosidase can be safely administered at home using our protocol in children with Pompe disease, including those with classic infantile Pompe disease who are more likely to develop IAR, provided that in-hospital treatment has been shown to be safe, and the appropriate infrastructure and clinical support are in place.

8 February 2023 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
APAns T. van der Ploeg
Ans T. van der Ploeg
NBNadine A.M.E. van der Beek
Nadine A.M.E. van der Beek
HHHannerieke (.J).M.P. van Den Hout
Hannerieke (.J).M.P. van Den Hout
HHHidde Huidekoper
Hidde Huidekoper